Trial

NCT05643573

A Study to Learn How Well the Study Treatment Asundexian Works and How Safe it is Compared to Apixaban to Prevent Stroke or Systemic Embolism in People With Irregular and Often Rapid Heartbeat (Atrial Fibrillation), and at Risk for Stroke
Phase IIITERMINATEDSAFETYConfidence: MEDIUM
Sponsor
Bayer
Collaborators
Condition
Prevention of Stroke or Systemic Embolism
Intervention
Asundexian (BAY2433334)
Why stopped
Independent Data Monitoring Committee (IDMC) recommendation to stop the study
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2024-12-09